Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Sell
44
TLSI Quote, Financials, Valuation and Earnings
Last price:
$5.25
Seasonality move
:
7.96%
Day range:
$5.30 - $5.51
52-week range:
$3.42 - $7.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.47x
P/B ratio:
--
Volume:
92.5K
Avg. volume:
189.5K
1-year change:
5.43%
Market cap:
$271.8M
Revenue:
$29.4M
EPS (TTM):
-$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$13.2M | -$0.13 | 48.18% | -67.11% | $11.50 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
ICUI
ICU Medical, Inc.
|
$542.9M | $1.69 | -13.68% | 316.67% | $180.83 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$5.44 | $11.50 | $271.8M | -- | $0.00 | 0% | 4.47x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7100 | $12.3077 | $201.5M | -- | $0.00 | 0% | 183.75x |
|
ICUI
ICU Medical, Inc.
|
$152.67 | $180.83 | $3.8B | -- | $0.00 | 0% | 1.62x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.48 | $14.20 | $172.5M | 32.43x | $0.00 | 0% | 1.28x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34.6M | -- | $0.00 | 0% | 19.32x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.65 | $1.50 | $91.4M | 64.00x | $0.00 | 0% | 0.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
461.2% | -0.444 | 14.71% | 2.54x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ICUI
ICU Medical, Inc.
|
39.35% | 0.229 | 46.61% | 1.02x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
|
$9.7M | -$9M | -936.41% | -- | -77.94% | -$3.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ICUI
ICU Medical, Inc.
|
$202.3M | $28.3M | -0.21% | -0.36% | 5.26% | $25M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
TriSalus Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns TLSI or CATX?
Perspective Therapeutics, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -12425.36%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TLSI or CATX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 111.4%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 354.16%. Given that Perspective Therapeutics, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TLSI or CATX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock TLSI or CATX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or CATX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.47x versus 183.75x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.47x -- $11.6M -$10.8M CATXPerspective Therapeutics, Inc.183.75x -- $209K -$26M
-
Which has Higher Returns TLSI or ICUI?
ICU Medical, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -0.63%. TriSalus Life Sciences, Inc.'s return on equity of -- beat ICU Medical, Inc.'s return on equity of -0.36%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M ICUIICU Medical, Inc.37.63% -$0.14 $3.5B -
What do Analysts Say About TLSI or ICUI?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 111.4%. On the other hand ICU Medical, Inc. has an analysts' consensus of $180.83 which suggests that it could grow by 18.45%. Given that TriSalus Life Sciences, Inc. has higher upside potential than ICU Medical, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than ICU Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 ICUIICU Medical, Inc.3 1 0 -
Is TLSI or ICUI More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.799, suggesting its less volatile than the S&P 500 by 20.087%.
-
Which is a Better Dividend Stock TLSI or ICUI?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or ICUI?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than ICU Medical, Inc. quarterly revenues of $537.7M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than ICU Medical, Inc.'s net income of -$3.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while ICU Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.47x versus 1.62x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.47x -- $11.6M -$10.8M ICUIICU Medical, Inc.1.62x -- $537.7M -$3.4M
-
Which has Higher Returns TLSI or INFU?
InfuSystem Holdings, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 6.19%. TriSalus Life Sciences, Inc.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About TLSI or INFU?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 111.4%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 67.45%. Given that TriSalus Life Sciences, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe TriSalus Life Sciences, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is TLSI or INFU More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock TLSI or INFU?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or INFU?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 32.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.47x versus 1.28x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.47x -- $11.6M -$10.8M INFUInfuSystem Holdings, Inc.1.28x 32.43x $36.5M $2.3M
-
Which has Higher Returns TLSI or VNRX?
VolitionRX Ltd. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of -862.39%. TriSalus Life Sciences, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About TLSI or VNRX?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 111.4%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 680.14%. Given that VolitionRX Ltd. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe VolitionRX Ltd. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is TLSI or VNRX More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock TLSI or VNRX?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or VNRX?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.47x versus 19.32x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.47x -- $11.6M -$10.8M VNRXVolitionRX Ltd.19.32x -- $627.3K -$5.4M
-
Which has Higher Returns TLSI or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -93.47% compared to TriSalus Life Sciences, Inc.'s net margin of 3.93%. TriSalus Life Sciences, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital TLSITriSalus Life Sciences, Inc.83.52% -$0.96 $7.4M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About TLSI or XTNT?
TriSalus Life Sciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 111.4%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 129.78%. Given that Xtant Medical Holdings, Inc. has higher upside potential than TriSalus Life Sciences, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than TriSalus Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TLSITriSalus Life Sciences, Inc.6 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is TLSI or XTNT More Risky?
TriSalus Life Sciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock TLSI or XTNT?
TriSalus Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TriSalus Life Sciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TLSI or XTNT?
TriSalus Life Sciences, Inc. quarterly revenues are $11.6M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. TriSalus Life Sciences, Inc.'s net income of -$10.8M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, TriSalus Life Sciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TriSalus Life Sciences, Inc. is 4.47x versus 0.71x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TLSITriSalus Life Sciences, Inc.4.47x -- $11.6M -$10.8M XTNTXtant Medical Holdings, Inc.0.71x 64.00x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
70
BNAI alert for Jan 26
Brand Engagement Network, Inc. [BNAI] is up 279.19% over the past day.
Buy
56
INTC alert for Jan 26
Intel Corp. [INTC] is down 5.77% over the past day.
Buy
64
BNR alert for Jan 26
Burning Rock Biotech Ltd. [BNR] is up 1.45% over the past day.
